Protective effect of a gonadotropin-releasing hormone analogue on chemotherapeutic agent-induced ovarian gonadotoxicity: A mouse model

European Journal of Obstetrics and Gynecology and Reproductive Biology

Volumn 149, Issue 2, 2010, Pages 182-185

  Tan, Shun Jen ^a   Yeh, Yu Chi ^b   Shang, Wei Jen ^a   Wu, Gwo Jang ^a   Liu, Jah Yao ^a   Chen, Chi Huang ^a  

^a TRI SERVICE GENERAL HOSPITAL   (Taiwan)

^b CATHAY GENERAL HOSPITAL   (Taiwan)

Author keywords

Fertility preservation; GnRH analogue; Gonadotoxicity; Ovarian protection; Primordial follicles

Indexed keywords

BUSULFAN; DIPHERELINE; TRIPTORELIN; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CANCER CHEMOTHERAPY; CONTROLLED STUDY; DRUG ACTIVITY; DRUG MEGADOSE; FEMALE; FEMALE FERTILITY; HISTOPATHOLOGY; LOW DRUG DOSE; MOUSE; NONHUMAN; OVARY DISEASE; OVARY FOLLICLE; PRIORITY JOURNAL; STATISTICAL SIGNIFICANCE;

EID: 77549087226     PISSN: 03012115     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.ejogrb.2009.12.028     Document Type: Article

References (25)

1. Lee S.J., Schover L.R., Partridge A.H., et al. American Society of Clinical Oncology recommendations on fertility preservation in cancer patients. J Clin Oncol 24 (2006) 2917-2931
2. Larsen E.C., Muller J., Schmiegelow K., Rechnitzer C., and Andersen A.N. Reduced ovarian function in long-term survivors of radiation- and chemotherapy-treated childhood cancer. J Clin Endocrinol Metab 88 (2003) 5307-5314
3. Blumenfeld Z., Avivi I., Eckman A., Epelbaum R., Rowe J.M., and Dann E.J. Gonadotropin-releasing hormone agonist decreases chemotherapy-induced gonadotoxicity and premature ovarian failure in young female patients with Hodgkin lymphoma. Fertil Steril 89 (2008) 166-173
4. Jeruss J.S., and Woodruff T.K. Preservation of fertility in patients with cancer. N Engl J Med 360 (2009) 902-911
5. Beck-Fruchter R., Weiss A., and Shalev E. GnRH agonist therapy as ovarian protectants in female patients undergoing chemotherapy: a review of the clinical data. Hum Reprod Update 14 (2008) 553-561
6. Meirow D., Lewis H., Nugent D., and Epstein M. Subclinical depletion of primordial follicular reserve in mice treated with cyclophosphamide: clinical importance and proposed accurate investigative tool. Hum Reprod 14 (1999) 1903-1907
7. Oktem O., and Oktay K. Quantitative assessment of the impact of chemotherapy on ovarian follicle reserve and stromal function. Cancer 110 (2007) 2222-2229
8. Reh A., Oktem O., and Oktay K. Impact of breast cancer chemotherapy on ovarian reserve: a prospective observational analysis by menstrual history and ovarian reserve markers. Fertil Steril 90 (2008) 1635-1639
9. Lutchman Singh K., Muttukrishna S., Stein R.C., et al. Predictors of ovarian reserve in young women with breast cancer. Br J Cancer 96 (2007) 1808-1816
10. Myers M., Britt K.L., Wreford N.G., Ebling F.J., and Kerr J.B. Methods for quantifying follicular numbers within the mouse ovary. Reproduction 127 (2004) 569-580
11. Dobrinski I., Ogawa T., Avarbock M.R., and Brinster R.L. Effect of the GnRH-agonist leuprolide on colonization of recipient testes by donor spermatogonial stem cells after transplantation in mice. Tissue Cell 33 (2001) 200-207
12. Mattison D.R., Chang L., Thorgeirsson S.S., and Shiromizu K. The effects of cyclophosphamide, azathioprine, and 6-mercaptopurine on oocyte and follicle number in C57BL/6N mice. Res Commun Chem Pathol Pharmacol. 31 (1981) 155-161
13. Sonmezer M., and Oktay K. Fertility preservation in female patients. Hum Reprod Update 10 (2004) 251-266
14. Blumenfeld Z., and von Wolff M. GnRH-analogues and oral contraceptives for fertility preservation in women during chemotherapy. Hum Reprod Update 14 (2008) 543-552
15. Clowse M.E., Behera M.A., Anders C.K., et al. Ovarian preservation by GnRH agonists during chemotherapy: a meta-analysis. J Womens Health (Larchmt) 18 (2009) 311-319
16. Ataya K., Rao L.V., Lawrence E., and Kimmel R. Luteinizing hormone-releasing hormone agonist inhibits cyclophosphamide-induced ovarian follicular depletion in rhesus monkeys. Biol Reprod 52 (1995) 365-372
17. Matsuo G., Ushijima K., Shinagawa A., et al. GnRH agonist acts as ovarian protection in chemotherapy induced gonadotoxicity: an experiment using a rat model. Kurume Med J 54 (2007) 25-29
18. Larson E.C., Muller J., Rechnitzer C., Schmiegelow K., and Andersen A.N. Diminished ovarian reserve in female childhood cancer survivors with regular menstrual cycles and basal FSH <10 IU/l. Hum Reprod 18 (2003) 417-422
19. Johnson J., Canning J., Kaneko T., Pru J.K., and Tilly J.L. Germline stem cells and follicular renewal in the postnatal mammalian ovary. Nature 428 (2004) 145-150
20. Anderson R.A., Themmen A.P., Al-Qahtani A., Groome N.P., and Cameron D.A. The effects of chemotherapy and long-term gonadotropin suppression on the ovarian reserve in premenopausal women with breast cancer. Hum Reprod 21 (2006) 2583-2592
21. Blumenfeld Z., Avivi I., Linn S., et al. Prevention of irreversible chemotherapy-induced ovarian damage in young women with lymphoma by a gonadotropin-releasing hormone agonist in parallel to chemotherapy. Human Reprod 11 (1996) 1620-1626
22. Oktay K., Briggs D., and Gosden R.G. Ontogeny of follicle-stimulating hormone receptor gene expression in isolated human ovarian follicles. J Clin Endocrinol Metab 82 (1997) 3748-3751
23. Dada T., Salha O., Allgar V., and Sharma V. Utero-ovarian blood flow characteristics of pituitary desensitization. Hum Reprod 16 (2001) 1663-1670
24. Badawy A., Elnashar A., El-Ashry M., and Shahat M. Gonadotropin-releasing hormone agonists for prevention of chemotherapy-induced ovarian damage: prospective randomized study. Fertil Steril 91 (2009) 694-697
25. Sverrisdottir A., Nystedt M., Johansson H., and Fornander T. Adjuvant goserelin and ovarian preservation in chemotherapy treated patients with early breast cancer: results from a randomized trial. Breast Cancer Res Treat 117 (2009) 561-567